1. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.
- Author
-
Paolisso, Pasquale, Bergamaschi, Luca, Cesaro, Arturo, Gallinoro, Emanuele, Gragnano, Felice, Sardu, Celestino, Mileva, Niya, Foà, Alberto, Armillotta, Matteo, Sansonetti, Angelo, Amicone, Sara, Impellizzeri, Andrea, Belmonte, Marta, Esposito, Giuseppe, Morici, Nuccia, Andrea Oreglia, Jacopo, Casella, Gianni, Mauro, Ciro, Vassilev, Dobrin, and Galie, Nazzareno
- Subjects
- *
MYOCARDIAL infarction , *CHRONIC kidney failure , *ACUTE kidney failure , *PEOPLE with diabetes , *TYPE 2 diabetes , *PRASUGREL , *CREATININE - Abstract
• Multicenter international registry with T2DM patients and AMI undergoing PCI. • SGLT2-I users exhibited significantly lower creatinine values at 72 h after PCI. • The rate of CI-AKI was significantly lower in SGLT2-I compared to non-SGLT2-I users. • SGLT2-I were identified as an independent predictor of reduced rate of CI-AKI. To analyze the association between chronic SGLT2-I treatment and development of contrast-induced acute kidney injury (CI-AKI) in diabetic patients with acute myocardial infarction (AMI) undergoing PCI. Multicenter international registry of consecutive patients with type 2 diabetes mellitus (T2DM) and AMI undergoing PCI between 2018 and 2021. The study population was stratified by the presence of chronic kidney disease (CKD) and anti-diabetic therapy at admission (SGLT2-I versus non-SGLT2-I users). The study population consisted of 646 patients: 111 SGLT2-I users [28 (25.2%) with CKD] and 535 non-SGLT2-I users [221 (41.3%) with CKD]. The median age was 70 [61–79] years. SGLT2-I users exhibited significantly lower creatinine values at 72 h after PCI, both in the non-CKD and CKD stratum. The overall rate of CI-AKI was 76 (11.8%), significantly lower in SGLT2-I users compared to non-SGLT2-I patients (5.4% vs 13.1%, p = 0.022). This finding was also confirmed in patients without CKD (p = 0.040). In the CKD cohort, SGLT2-I users maintained significantly lower creatinine values at discharge. The use of SGLT2-I was an independent predictor of reduced rate of CI-AKI (OR 0.356; 95%CI 0.134–0.943, p = 0.038). In T2DM patients with AMI, the use of SGLT2-I was associated with a lower risk of CI-AKI, mostly in patients without CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF